Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Entyvio[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[3] 94, 96, 97 💬
2ENTYVIO - 300 MG - POLVERE PE RCONCENTRATO PER SOLUZIONE PER INFU[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 97 💬
3ENTYVIO - 300 MG - POLVERE PE RCONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[2] 96, 97 💬
4ENTYVIO - 300 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 97 💬
5Entyvio 300 mg[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 97 💬
6Entyvio 300mg[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 97 💬
7Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab
(Entyvio (TN))		[5] Adalimumab,
Golimumab,
Infliximab,
Ustekinumab,
Vedolizumab (Entyvio)		[5] Adalimumab ,
Infliximab ,
Golimumab ,
Vedolizumab (Entyvio (TN)),
Ustekinumab 💬 		[6] IL12A,
IL12B,
IL23A,
ITGA4,
ITGB7,
TNF 💬 		[81] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Arrhythmogenic right ventricular cardiomyopathy, Asthma, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, ECM-receptor interaction, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬[2] 96, 97 💬
8Infliximab, adalimumab, golimumab, vedolizumab, ustekinumab
(Entyvio (TN))		[5] Adalimumab,
Golimumab,
Infliximab,
Ustekinumab,
Vedolizumab (Entyvio)		[5] Adalimumab ,
Infliximab ,
Golimumab ,
Vedolizumab (Entyvio (TN)),
Ustekinumab 💬 		[6] IL12A,
IL12B,
IL23A,
ITGA4,
ITGB7,
TNF 💬 		[81] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Arrhythmogenic right ventricular cardiomyopathy, Asthma, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, ECM-receptor interaction, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬[1] 97 💬
9MLN0002 (Vedolizumab)
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[2] 96, 97 💬
10Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra[3] Infliximab,
Ustekinumab,
Vedolizumab (Entyvio)		[3] Infliximab ,
Vedolizumab (Entyvio (TN)),
Ustekinumab 💬 		[6] IL12A,
IL12B,
IL23A,
ITGA4,
ITGB7,
TNF 💬 		[81] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Arrhythmogenic right ventricular cardiomyopathy, Asthma, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, ECM-receptor interaction, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬[1] 96 💬
11VEDOLIZUMAB
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[3] 94, 96, 97 💬
12Vedolizumab (Genetical Recombination)
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 96 💬
13Vedolizumab 108 mg SC
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 97 💬
14Vedolizumab 300 mg
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 97 💬
15Vedolizumab 300 MG Injection [Entyvio][1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 96 💬
16Vedolizumab 300 mg IV
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 97 💬
17Vedolizumab Injection
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 97 💬
18Vedolizumab Intravenous (IV), Vedolizumab Subcutaneous (SC), Placebo IV
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 97 💬
19Vedolizumab intravenous injection
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[2] 96, 97 💬
20Vedolizumab IV
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[3] 94, 96, 97 💬
21Vedolizumab IV (Entyvio¿)[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 96 💬
22Vedolizumab IV (Entyvio™)[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 96 💬
23Vedolizumab IV 300 mg
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 96 💬
24Vedolizumab IV, Placebo IV, Placebo SC
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 97 💬
25Vedolizumab IV, Placebo SC
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 97 💬
26Vedolizumab SC
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[2] 96, 97 💬
27Vedolizumab SC 108 mg
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[2] 96, 97 💬
28Vedolizumab subcutaneous injection
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[2] 96, 97 💬
29Vedolizumab, Entyvio[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[2] 96, 97 💬
30Vedolizumab, Ustekinumab, or Tofacitinib
(Entyvio (TN))		[3] Tofacitinib,
Ustekinumab,
Vedolizumab (Entyvio)		[3] Vedolizumab (Entyvio (TN)),
Ustekinumab ,
Tofacitinib 💬 		[9] IL12A,
IL12B,
IL23A,
ITGA4,
ITGB7,
JAK1,
JAK2,
JAK3,
TYK2 💬 		[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, Arrhythmogenic right ventricular cardiomyopathy, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, ECM-receptor interaction, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Focal adhesion, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pertussis, Primary immunodeficiency, Prolactin signaling pathway, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Yersinia infection 💬[1] 97 💬
31Vedolizumab-800CW
(Entyvio (TN))		[1] Vedolizumab (Entyvio)[1] Vedolizumab (Entyvio (TN)) 💬 [2] ITGA4,
ITGB7 💬 		[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬[1] 96 💬